20.03.2020 As part of the immanent advancement of cell-based liquid biopsy, we are happy to announce the filing of the latest patent application of the SanoLibio Project introducing the discovery …
SanoLibio is an internationally recognized biomedical technology innovator. Having understood that it is firstly technology that enables advancement, we have opened a new window with our proprietary automated cell separation platform into rare blood cell analysis which is seen as the next generation of liquid biopsy diagnostics potentially managing many health issues of our times, including cancer, myocardial infarction, diabetes and many more. Our unique rare cell enrichment platform called “Walderbach” is one of the very few worldwide to allow comprehensive ultra-rare cell enrichment and detection which is a crucial detail for the understanding of disease evolution and delineation that ultimately leads to better health care.
SanoLiBio is a German based medtech start-up focusing on the enrichment of rare cells in general and circulating tumor cells (CTCs) in particular taken from liquid biopsy. CTCs are seen as THE early stage cancer biomarkers. They are the first detectable sign of cancer in the human body at all.
In Phase I we will establish Walderbach as new benchmark in rare cell enrichment internationally from 2020 onwards. Phase II marks the entry into diagnostic services.